Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1987-04-06
1989-12-26
Shah, PhD, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 45, A61K 31485, C07D48908
Patent
active
048898600
ABSTRACT:
A potent, selective opioid receptor agonist or antagonist exhibiting properties useful for a longacting analgesic or opiate abuse treatment agent or appetite suppressant having the general formula: ##STR1## wherein R is methyl, cyclopropylmethyl or allyl, and R.sub.1 is an unsubstituted or substituted aryl, aralkyl, heteroaryl, heteroaralkyl or a cycloalkyl group with or without a heteroatom like S,O,N; and the pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 3135758 (1964-06-01), Fishman
patent: 3153042 (1964-10-01), Fishman
patent: 3320262 (1967-05-01), Lewenstein et al.
Baskin, D. S., Y. Hosobuchi, H. H. Loh and N. M. Lee, Dynorphin.sub.1-13 Improves Survival in Cats with Focal Cerebral Ischemia. Nature, 312: 551-552, 1984.
Kuroda, H., D. S. Baskin, T. Matsui, H. H. Loh, Y. Hosobuchi and N. M. Lee, Effects of Dynorphin.sub.1-13 on Opiate Binding and Dopamine and GABA Uptake in Stroked Cat Brain. Brain Res., 379: 68-74, 1986.
Silvia and Tang. Protection of Ischemia--Induced Cerebral Edema by the Kappa Opioid Agonist U--50488, In: Pharmacology of Cerebral Ischemia, edt by J. Krieglstein, Elsevier, 1986. pp. 381-384.
Silvia, Slizgi, Ludens and Tang. Protection from Ischemia--Induced Cerebral Edema in the Rat by U-50488H, a Kappa Opioid Receptor Agonist. Brain Res., 403: 52-57, 1987.
Lason, Simpson and McGinty. The Effects of the Kappa Opioid Receptor Agonist U50488H on Kainic Acid Neurotoxicity. Soc. Neurosci. Abstr. 13:1306, 1987.
Tang, Protection from Cerebral Ischemia by U50,488E, A Specific Kappa Opioid Analgesic Agent, Life Sci., 37: 1475-1482, 1985.
Ochoa, Jackson, Aaron and VonVoigtlander, Mechanism of Anticonvulsant and Cerebroprotective Activity of U-50488H and U-54494A. Soc. Neurosci. Abstr. 13: 765, 1987.
VonVoigtlander, Hall, Ochoa, Lewis and Triezenberg, U-54494A: A Unique Anticonvulsant Related to Kappa Opioid Agonists. J. Pharmacol. Exp. Ther. 234: 542-547, 1987.
Tortella, Robles and Holaday, U50,488, A Highly Selective Kappa Opioid: Anticonvulsant Profile in Rats, J. Pharmacol. Exp. Ther. 237: 49-53, 1986.
Moises and Walker, Electrophysiological Effects of Dynorphin Peptides on Hippocampald Pyramidal cells in rat, Eur. J. Pharmaco; Bradley and Brooks, A Microiontophoretic Study of the Actions of 1th, 2 and K-Opiate Receptor Agonists in the Rat Brain. Br. J. Pharmac. 83:763-772, 1984.
Bernton, Long and Holaday, Opioids and Neuropeptides: Mechanisms in Circulatory Shock, Fedn. Proc. 44: 290-299, 1985.
Holaday, Cardiovascular Consequences of Endogenous Opiate Antagonism, Biochem. Pharmacol. 32: 573-585, 1983.
Feuerstein, The Opioid System and Central Cardiovascular Control: Analysis of Controversies, Peptides 6 (Suppl. 2): 51-56, 1985.
D'Amato and Holaday, Multiple Opioid Receptors in Endotoxic Shock: Evidence For Delta Involvement and Mu--Delta Interactions in Vivo. Proc. Natl. Acad. Sci. USA, 81: 2898-2901, 1984.
Long, Ruvio, Glatt and Holaday, ICI 174,864, A Putative Delta Opioid Antagonist, Reverses Endotoxemic Hypotension: Pretreatment with Dynorphin.sub.1-13, A K Agonistblocks This Action. Neuropeptides 5: 291-294, 1984.
McKenzie, Anselmo and Muldoon, Nalbuphine's Reversal of Hypovolemic Shock in the Anesthetized Rat. Circ. Shock 17: 21-33, 1985.
Paciorek, Todd and Waterfall, The Effects of Meptazinol in Comparison with Pentazocine, Morphone and Nalozone in a Rat Model of Anaphylactic Shock, Br. J. Pharmacol. 84:469-475, 1985.
Shavit, Terman, Martin, Lewis, Liebeskind an Gale, Stress, Opioid Peptides, the Immune System and Cancer. J. Immunol. 135: 834s-837s, 1985.
Teschemacher and Schweigerer, Opioid Peptides: Do they have Immunological Significance? Trends Pharmacol. Sci. 6: 368-370, 1985.
Holaday, Endogenous Opioids and Their Receptors, Current Concepts. Kalamazoo, MI, Scope Publications, Upjohm, 1985.
Shavit, Depaulis, Martin, Terman, Pechnick, Zane, Gale and Liebeskind, Involvement of Brain Opiate Receptors in the Immune--Suppressive Effect of Morphine. Proc. Natl. Acad. Sci. USA, 83: 7114-7117, 1986.
Shavit, Lewis, Terman, Gale and Liebeskind, Opioid Peptides Mediate the Suppressive Effect of Stress on Natural Killer Cell Cytoxicity, Science, 223, 188-190, 1984.
Rapoport, et al., J. Organic Chem., vol. 15, pp. 1103-06, (1950).
Bentley, "The Chemistry of the Morphine Alkaloids", Oxford (1954), pp. 180, 259.
Sawa et al., Tetrahedron, vol. 24, pp. 6185-6196, (1968).
Hahn, et al., J. Pharm. & Pharmacology, vol. 35(17), pp. 833-36, (12/83).
Ko, et al., J. Med. Chem., vol. 27(12), pp. 1727-1729, (12/84).
Koolpe, et al., J. Med. Chem., vol. 28(7), pp. 949-957, (07/85).
Mohamed, et al., Chemical Abstracts, vol. 104, 88886t, (196).
Mavunkel Babu J.
Rzeszotarski Waclaw J.
Nova Pharmaceutical Corporation
Rivers Diana G.
Shah, PhD Mukund J.
LandOfFree
Oximes of oxymorphone, naltrexone and naloxone as potent, select does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oximes of oxymorphone, naltrexone and naloxone as potent, select, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oximes of oxymorphone, naltrexone and naloxone as potent, select will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1577423